Large genetic study links telomere-related polygenic risk to distinct idiopathic pulmonary fibrosis subgroups, improving disease prediction.

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

Please provide your email address to receive an email when new articles are posted on . The FDA based nerandomilast’s approval on results from two trials, one of which was the FIBRONEER-IPF trial.

PET-MPs may exacerbate IPF by inducing oxidative stress, mitochondrial damage, and inflammation in pulmonary cells, leading to chronic lung injury. The study identified AKT1, PIM1, and PIK3CD as core ...